ORIGINAL ARTICLE
Expression and clinical significance of KDM5A, KDM5B, and FOXO1 in endometrial cancer
1
Department of Obstetrics and Gynecology, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, China
2
Department of Obstetrics and Gynecology, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Clinical Research Center for Cancer, Nanchang, Jiangxi, China
Submission date: 2023-11-22
Acceptance date: 2024-01-06
Publication date: 2024-05-16
Pol J Pathol 2024;75(2):83-96
KEYWORDS
TOPICS
ABSTRACT
There is growing evidence that the KDM5 family of histone demethylases plays a causal role in human cancer. However, few studies have been reported on the KDM5 family in endometrial carcinoma (EC). Moreover, it was found that there was some correlation between the KDM5 family and FOXO1 in EC. The current study was performed to explore the expressions of KDM5A, KDM5B, and FOXO1 in endometrioid adenocarcinoma detected by immunohistochemistry; paracancer endometrium, simple hyperplastic endometrium, and normal endometrium were used as control groups to explore the possible diagnostic value of KDM5A and KDM5B expression in endometrioid adenocarcinoma, with the aim of evaluating the potential of this marker in predicting the prognosis of endometrioid adenocarcinoma.
REFERENCES (86)
1.
Koh WJ, Abu-Rustum NR, Bean S, et al. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16: 170-199.
2.
Moir-Meyer GL, Pearson JF, Lose F, et al. Rare germline copy number deletions of likely functional importance are implicated in endometrial cancer predisposition. Hum Genet 2015; 134: 269-278.
3.
Yu XY, Ma LG. Progress in clinical diagnosis and treatment of endometrial carcinoma. J Clin Med Res Pract 2017; 2: 190-193.
4.
Hu D, Jablonowski C, Cheng PH, et al. KDM5A regulates a translational program that controls p53 protein expression. iScience 2018; 9: 84-100.
5.
Guo X, Guan MM, Liu CH, et al. Application of hysteroscopy in diagnosis and treatment of endometrial cancer. Chin J Pract Gynecol Obst 2017; 33: 13-15.
6.
Xiaojun C, Xuezhen L. Selection and implementation of fertility preservation in early endometrial cancer. Chinese Pract Gynecol Obst J 2019; 35: 14-19.
7.
China research hospital association of obstetrics and gynecology professional committee. Clin Res Pract 2019; 20: 369-373.
8.
Lin Z Q. Paying attention to the standardized and individualized treatment of endometrial cancer. Chin J Practical Gynecol Obst 2017; (05): 5-7.
9.
Zhang LW, Ma J, Jin Y, Hu QB, Li Y, Wang Y. Expression of KDM5B gene in ovarian cancer and its effect on drug resistance in ovarian cancer. Adv Modern Obst Gynecol 2017; 26: 161-164.
10.
Hou J, Wu J, Dombkowski A, et al. Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer. Am J Transl Res 2012; 4: 247-256.
11.
Hinohara K, Wu HJ, Vigneau S, et al. KDM5 histone demethylase activity links cellular transcriptomic heterogeneity to therapeutic resistance. Cancer Cell 2019; 35: 330-332.
12.
Liu X, Greer C, Secombe J. KDM5 interacts with Foxo to modulate cellular levels of oxidative stress. PLoS Genet 2014; 10: e1004676.
13.
Qing-Lei G, Fei Y, Jing L, et al. PTEN coding product: a marker for tumorigenesis and progression of endometrial carcinoma. Ai Zheng 2003; 22: 640-644.
14.
Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics. CA Cancer J Clin 2020; 2020: 10.3322/caac.21601.
15.
Nagle CM, Olsen CM, Ibiebele TI, et al. Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis. Eur J Nutr 2013; 52: 705-715.
16.
Zhang P, Gao K, Jin X, et al. Endometrial cancer -associated mutants of SPOP are defective in regulating estrogen receptor - protein turnover. Cell Death Dis 2015; 6: e1687.
17.
Siegel RL, Miller KD, Jemal A. Cancer statistics 2016. CA Cancer J Clin 2016; 66: 7-30.
18.
Kuramoto H. Cytological characteristics of endometrial phasing using the specimens prepared with the liquid-based procedure: comparison with the conventional procedure. Acta Cytol 2016; 60: 429-437.
19.
Chen XL, Jin P, Zhao J, et al. Application of modified endometrial sampler in the early diagnosis of endometrial lesion biopsy. Chin J Exp Diag 2015; 19: 1096-1098.
20.
LI L, WANG L, SONG P, et al. Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis. Mol Cancer 2014; 13: 81.
21.
Coffer PJ, Burgering BMT. Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol 2004; 4: 889-899.
22.
Horton JR, Engstrom A, Zoeller EL, et al . Characterization of a linked Jumonji domain of the KDM5/JARID1 family of histone H3 lysine 4 demethylases. J Biol Chem 2016; 291: 2631-2646.
23.
Beshiri ML, Islam A, Dewaal DC, et al. Genome-wide analysis using CHiP to identify isoform-specific gene targets. J Vis Exp 2010; (41): e2101.
24.
Yang GJ, Zhu MH, Lu XJ, et al. The emerging role of KDM5A in human cancer. J Hematol Oncol 2021; 14: 30.
25.
Váraljai R, Islam AB, Beshiri ML, et al. Increased mitochondrial function downstream from KDM5A histone demethylase rescues differentiation in pRB-deficient cells. Genes Dev 2015; 29: 1817-1834.
26.
Dubot C, Bernard V, Sablin MP, et al. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival. Eur J Cancer 2018; 91: 47-55.
27.
Vieira FQ, Costa-Pinheiro P, Ramalho-Carvalho J, et al. Deregulated expression of selected histone methylases and demethylases in prostate carcinoma. Endocr Relat Cancer 2013; 21: 51-61.
28.
Jia C, WANG J, Shao GB, et al. Expression of LSD1 and KDM5 family in ovarian cancer cells and the effect of LSD1 on cell proliferation and migration. J Southeast Univ 2016; 35: 350-354.
29.
Kong LL, Man DM, Wang T, et al. siRNA targeting RBP 2 inhibits expression, proliferation,tumorigenicity and invasion in thyroid carcinoma cells. Oncol Lett 2015; 10: 3393-3398.
30.
Zhou M, Zeng J, Wang X, et al. Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia. Oncotarget 2015; 6: 1249-1261.
31.
Dai B, Huang H, Guan F, et al. Histonedemethylase KDM5A inhibits glioma cells migration and invasion by down regulating ZEB1. Biomed Pharmacother 2018; 99: 72-80.
32.
Feng T, Wang Y, Lang Y, et al. KDM5A promotes proliferation and EMT in ovarian cancer and closely correlates with PTX resistance. Mol Med Rep 2017; 16: 3573-3580.
33.
Gong F, Clouaire T, Aguirrebengoa M, et al. Histone demethylase KDM5A regulates the ZMYND8-NuRD chromatin remodeler to promote DNA repair. J Cell Biol 2017; 216: 1959-1974.
34.
Sharma SV, Lee DY, Li B, et al. A chromatin-mediated rever- sible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141: 69-80.
35.
Pilka ES, James T, Lisztwan JH. Structural definitions of Jumonji family demethylase selectivity. Drug Discovery Today 2015; 20: 743-749.
36.
Yang X, Ziqi Z, Gang H, et al. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci U S A 2007; 104: 9226-19231.
37.
Johansson C, Velupillai S, Tumber A, et al. Structural analysis of human KDM5B guides histone demethylase inhibitor development. Nat Chem Biol 2016; 12: 539-545.
38.
Horton JR, Engstrom A, Zoeller EL, et al. Characterization of a linked Jumonji domain of the KDM5/JARID1 family of histone H3 lysine 4 demethylases. J Biol Chem 2016; 291: 2631-2646.
39.
Patsialou A, Wilsker D, Moran E. DNA-binding properties of ARID family proteins. Nucleic Acids Res 2005; 33: 66-80.
40.
Sanchez R, Zhou MM. The PHD finger: a versatile epigenome reader. Trends Biochem Sci 2011; 36: 364-372.
41.
Lu PJ, Sundquist K, Baeckstrom D, et al. A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer. J Biol Chem 1999; 274: 15633-15645.
42.
Zhang Y, Yang H, Guo X, et al. The PHD1 finger of KDM5B recognizes unmodified H3K4 during the demethylation of histone H3K4me2/3 by KDM5B. Protein Cell 2014; 5: 837-850.
43.
Viré E, Curtis C, Davalos V, et al. The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31. Molecular Cell 2014; 53: 806- 818.
44.
Rotili D, Mai A. Targeting histone demethylases a new avenue for the fight against cancer. Genes Cancer 2011; 2: 663-679.
45.
Barrett A, Madsen B, Copier J, et al. PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: a new cancer/testis antigen? Int J Cancer 2002; 101: 581-588.
46.
Denis H, Van Grembergen O, Delatte B, et al. MicroRNAs regulate KDM5 histone demethylases in breast cancer cells. Mol Biosyst 2016; 12: 404-413.
47.
Bamodu OA, Huang WC, Lee WH, et al. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448. BMC Cancer 2016; 16: 160.
48.
Facompre ND, Harmeyer KM, Sole X, et al. JARID1B enables transit between distinct states of the stem-like cell population in oral cancers [published correction appears in Cancer Res 2017; 77: 7136]. Cancer Res 2016; 76: 5538-5549.
49.
Veerakumarasivam A, Kodiappan R, Chan SC, Razack AH. Abstract 5213: microRNA-mediated loss of KDM5B expression leads to suppression of the malignant bladder cancer phenotype. J Nucl Mat 2014; 74: 5213-5213.
50.
Cui Z, Song L, Hou Z, et al. PLU-1/JARID1B overexpression predicts proliferation properties in head and neck squamous cell carcinoma. Oncol Rep 2015; 33: 2454-2460.
51.
Fang L, Zhao J, Wang D, Zhu L, Wang J, Jiang K. Jumonji AT-rich interactive domain 1B overexpression is associated with the development and progression of glioma [published correction appears in Int J Mol Med 2016; 38: 976]. Int J Mol Med 2016; 38: 172-182.
52.
Cui G, Liu D, Li W, et al. Original research: miR-194 inhibits proliferation and invasion and promotes apoptosis by targeting KDM5B in esophageal squamous cell carcinoma cells. Exp Biol Med (Maywood) 2017; 242: 45-52.
53.
Tarnowski M, Czerewaty M, Deskur A, et al. Expression of cancer testis antigens in colorectal new prognostic and therapeutic implications. Dis Markers 2016; 2016: 1-9.
54.
Wang L, Mao Y, Du G, He C, Han S. Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer. Tumour Biol 2015; 36: 2465-2472.
55.
Li Q, Shi L, Gui B, et al. Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14. Cancer Res 2011; 71: 6899-6908.
56.
Li L, Shou H, Wang Q, Liu S. Investigation of the potential theranostic role of KDM5B/miR-29c signaling axis in paclitaxel resistant endometrial carcinoma. Gene 2019; 694: 76-82.
57.
Wong PP, Miranda F, Chan KV, et al. Histone demethylase KDM5B collaborates with TFAP2C and MYC to repress the cell cycle inhibitor p21cip (CDKN1A). Mol Cell Biol 2012; 32: 1633-1644.
58.
Maiese K, Chong ZZ, Shang YC, et a1. Clever cancer strategies with FoxO transcription- factors. Cell Cycle 2008; 7: 3829-3839.
59.
Salih DA, Brunet A. FoxO transcription factors in the maintenance of cellular homeostasis during aging. Curr Opin Cell Biol 2008; 20: 126-136.
60.
Kaestner KH, Knochel W, Martinez DE. Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev 2000; 14: 142-146.
61.
Obsi T, Obsilova V. Structure/function relationshipsun-derlying regulation of FOXO transcription factors. Oncogene 2008; 27: 2263-2275.
62.
Espenshade PJ. SREBPs: sterol-regulated transcription factors. J Cell Sci 2006; 119: 973-976.
63.
Sedding DG. FoxO transcription factors in oxidative stress response and ageing – a new fork on the way to longevity? Biol Chem 2008; 389: 279-283.
64.
Vogt PK, Jiang H, Aoki M. Triple layer control:phospho-rylation,acetylation and u biquitination of FOXO proteins. Cell Cycle 2005; 4: 908-913.
65.
Biggs WH, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. Protein kinase B/A kt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHRl. Proe Natl Acad Sci U S A l999; 96: 7421-7426.
66.
Katoh M, Igarashi M, Fukuda H, Nakagama H, Katoh M. Cancer geneticsand genomics of human FOX family genes. Cancer Lett 2013; 328: 198-206.
67.
Greer EL, Brunet A. FOXO transcription factors in ageing and cancer. Acta Physiol (Oxf.) 2008; 192: 19-28.
68.
Ma Q, Fu W, Li P, et a1. FOXO1 mediates PTEN suppression of androgen receptor N-and C-terminal interactions and coactivator recruitment. Mo1 Endocrinol 2009; 23: 213- 225.
69.
Dong XY, Chen C, Sun X, et a1. FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting an drogen receptor signaling in prostate cancer. Cancer Res 2006; 66: 6998- 7006.
70.
Li P, Lee H, Guo S, et a1. AKT – independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mo1 Cell Bio 2003; 23: 104-118.
71.
Silva J, Cavazos DA, Donzis E, et al. Akt induced tamoxifen resistance is associated with altered FKHR regulation. Cancer Invest 2007; 25: 569-573.
72.
Guttilla IK. White BA. Coordinate regulation of FOXO1 by miR-27a.miR-96 and miR-182 breast cancer cells. J Biol Chem 2009; 284: 23204-23216.
73.
Choi HK, Cho KB, Phuong NT, et al. SIRT1-mediated FOXO1 deacetylation is essential for multidrug resistance-associated protein 2 expression in tamoxifen-resistant breast cancer cells. Mol Pharm 2013; 107: 2517-2527.
74.
Lee SY, Lee GR, Woo DH, et al. Depletion of aurora a leads to upregulation of FOXO1 to induce cell cycle arrest in hepa-tocellular carcinoma cells. Cell Cycle 2013; 12: 67-75.
75.
Xu D, He X, Chang Y, et al. Inhibition of miR-96 expression reduces cell proliferation and clonogenicity of HepG 2 hepatoma cells. Oncol Rep 2013; 29: 653-661.
76.
Beales IL, Ogunwobi O, Cameron E, et al. Activation of Akt is increased in the dysplasia- carcinoma sequence in Barrett’s oesophagus and contributes to increased proliferation and inhibition of apoptosis :a hist0pathological and functional study. BMC Cancer 2007; 7: 97.
77.
Jothi M, Mal M, Keller C, et al. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma. Mol Cancer Ther 2013; 12: 2663-2674.
78.
Xie L, Ushmorov A, Leithauser F, et al. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood 2012; 119: 3503-35l1.
79.
Huang H, Regan KM, Wang F, et al. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci 2005; 102: 1649-1654.
80.
Lahav-Baratz S, Ben-Izhak O, Sabo E, et al. Decreased level of the cell cycle regulator p27 and increased level of its ubiquitin ligase Skp2 in endometrial carcinoma but not in normasecretory or in hyperstimulated endometrium. Mol Hum Rep 2004: 10: 567-572.
81.
Myatt SS, Wang J, Monteiro LJ, et al. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 2010; 70: 367-377.
82.
Goto T, Takano M, Albergaria A, et al. Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene 2008; 27: 9-19.
83.
Hoekstra AV, Ward EC, Hardt JL, et al. Chemosensitization of endometrial cancer cells through AKT inhibition involves FOXO1. Gynecol Oncol 2008; 108: 609-618.
84.
Mazumdar A, Kumar R. Estrogen regulation of Pak1 and FKHR pathways in breast cancer cells. FEBS Lett 2003; 535: 6-10.
85.
Korani M, Fallah S. Evaluating the p-FOXO1/FOXO1 ratio: an alternative strategy for endometrial cancer diagnosis. Int J Clin Med 2015; 6: 217-226.
86.
Liu X, Greer C, Secombe J. KDM5 interacts with FOXO to modulate cellular levels of oxidative stress. PLoS Gen 2014; 10: e1004676.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
